Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pivotal Therapeutics, a pharmaceutical company with a focus on the treatment of cardiovascular disease, is planning to introduce its proprietary Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acid formulation Vascazen in North America.
Subscribe to our email newsletter
Vascazen is a medical food to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating EPA and DHA Omega-3 Fatty acids.
Pivotal Therapeutics will be launching the product at both the Canadian Cardiovascular Congress (CCC) Vancouver 2011 Conference and the American Heart Association’s (AHA) Scientific Sessions 2011, In October and November 2011, respectively.
Pivotal Therapeutics president Rachelle Mac Sweeney said the company will accept orders for Vascazen at the conferences.Sweeney said.